Search
Carboplatin Treatment Options in United Kingdom
A collection of 302 research studies where Carboplatin is the interventional treatment. These studies are located in the United Kingdom . Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
37 - 48 of 302
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Active Not Recruiting
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epco... Read More
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied.
Trial details include:
* The treatment duration for each participant depends upon which arm of treatment they are assigned to.
* The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks.
* All participants will receive active drug; no one will be given placebo.
Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned.
Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +57 locations
University of Alabama at Birmingham, Birmingham, Alabama
Cedars-Sinai Medical Center, Los Angeles, California
David Geffen School of Medicine at UCLA, Los Angeles, California
University of California San Francisco, San Francisco, California
Dana Farber Cancer Institute, Boston, Massachusetts
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey
Mount Sinai, New York, New York
Memorial Sloan Kettering CC, New York, New York
Levine Cancer Center, Charlotte, North Carolina
UT Southwestern Medical Center, Dallas, Texas
Austin Health, Heidelberg, Not set
Linear Clinical Research Limited, Nedlands, Not set
AZ Sint-Jan, Brugge, Not set
Universitair Ziekenhuis Gent, Gent, Not set
CHU UCL Namur Site Godinne, Yvoir, Not set
Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set
Fakultni nemocnice Ostrava, Ostrava - Poruba, Not set
Fakultni nemocnice v Motole, Prague, Not set
Vseobecna Fakultni Nemocnice, Praha 2, Not set
Århus Hospital, Arhus, Not set
Rigshospitalet, Copenhagen, Not set
Odense University Hospital, Odense, Not set
Vejle Sygehus, Vejle, Not set
Tampere University Hospital, Helsinki, Not set
Kuopio University Hospital, Kuopio, Not set
HUS Cancer Center, Lahti, Not set
Hopital Claude Huriez - CHRU Lille, Lille, Not set
Hôpital de la Timone, Marseille, Not set
Hôpital Saint-Louis, Paris, Not set
Centre Hospitalier Lyon Sud, Pierre-Bénite, Not set
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Not set
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna, Not set
Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS, Candiolo, Not set
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Not set
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan, Not set
Fondazione IRCCS Policlinico San Matteo, Pavia, Not set
Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Not set
Amsterdam UMC, Locatie VUMC, Amsterdam, Not set
Universitair Medisch Centrum Groningen (UMCG), Groningen, Not set
Leids Universitair Medisch Centrum, Leiden, Not set
Maastricht University Medical Center, Maastricht, Not set
Erasmus Medisch Centrum, Rotterdam, Not set
UMC Utrecht, Utrecht, Not set
Oslo Universitetssykehus HF, Radiumhospitalet, Oslo, Not set
ICO l Hospitalet, Barcelona, Not set
Hospital Universitari Vall d'Hebron, Barcelona, Not set
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital Universitario de Salamanca, Salamanca, Not set
Södra Älvsborgs Sjukhus, Borås, Not set
Sahlgrenska Sjukhuset, Göteborg, Not set
Skånes Universitetssjukhus, Lund, Not set
Karolinska Universitetssjukhuset, Solna, Not set
Akademiska Sjukhuset, Uppsala, Not set
The Christie NHS Foundation Trust, Manchester, Not set
Freeman Hospital, Newcastle Upon Tyne, Not set
Derriford Hospital, Plymouth, Not set
Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Terminated
The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization/expansion phase (Part 2). Part 1 is comprised of three sub-parts: SAR444881 administered alone (Sub-Part 1A), SAR444881 administered in combination with pembrolizumab (Sub-Part 1B), and SAR444881 administered in combination with cetuximab... Read More
The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization/expansion phase (Part 2). Part 1 is comprised of three sub-parts: SAR444881 administered alone (Sub-Part 1A), SAR444881 administered in combination with pembrolizumab (Sub-Part 1B), and SAR444881 administered in combination with cetuximab (Sub-Part 1C). Part 2 is composed of two sub-parts: a dose optimization part where up to two doses of SAR444881 per indication are administered in combination with pembrolizumab, cetuximab, and/or carboplatin and pemetrexed (Sub-Part 2A); and a dose expansion part where SAR444881 is administered alone (Sub-Part 2B). In Sub-Part 2A, a two-stage design will be implemented to conduct dose optimization for each indication with combination therapy- Stage 1 (Preliminary Assessment) and Stage 2 (Randomization). Study is non-randomized except Stage 2 of Sub-Part 2A which will use randomization. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Mayo Clinic Hospital- Site Number : 8400003, Phoenix, Arizona +17 locations
Mayo Clinic Hospital- Site Number : 8400003, Phoenix, Arizona
City of Hope Comprehensive Cancer Center- Site Number : 8400002, Duarte, California
University of Colorado- Site Number : 8400012, Aurora, Colorado
Smilow Cancer Center at Yale-New Haven- Site Number : 8400001, New Haven, Connecticut
Clermont Oncology Center- Site Number : 8400005, Clermont, Florida
Mid Florida Hematology and Oncology Center- Site Number : 8400006, Orange City, Florida
Mercy Cancer Center - MercyOne Richard Deming Cancer Center- Site Number : 8400011, Des Moines, Iowa
Norton Cancer Institute - Downtown Women's Cancer Center- Site Number : 8400004, Louisville, Kentucky
Mayo Clinic Hospital Rochester- Site Number : 8400007, Rochester, Minnesota
Investigational Site Number : 1240001, Barrie, Ontario
Investigational Site Number : 1240003, Sherbrooke, Quebec
Investigational Site Number : 3760004, Haifa, Not set
Investigational Site Number : 3760005, Jerusalem, Not set
Investigational Site Number : 3760001, Petah Tikva, Not set
Investigational Site Number : 3760003, Ramat Gan, Not set
Investigational Site Number : 3760002, Tel Aviv, Not set
Investigational Site Number : 8260003, London, London, City Of
Investigational Site Number : 8260002, Leeds, Not set
Conditions: Cancer, Neoplasm
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Recruiting
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Research Site, Phoenix, Arizona +179 locations
Research Site, Phoenix, Arizona
Research Site, Duarte, California
Research Site, Santa Rosa, California
Research Site, Aurora, Colorado
Research Site, Jacksonville, Florida
Research Site, Atlanta, Georgia
Research Site, Chicago, Illinois
Research Site, Baltimore, Maryland
Research Site, Rochester, Minnesota
Research Site, Saint Louis, Missouri
Research Site, East Brunswick, New Jersey
Research Site, Commack, New York
Research Site, Valhalla, New York
Research Site, Cleveland, Ohio
Research Site, Cleveland, Ohio
Research Site, Cleveland, Ohio
Research Site, Columbus, Ohio
Research Site, Independence, Ohio
Research Site, Portland, Oregon
Research Site, Portland, Oregon
Research Site, Portland, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Houston, Texas
Research Site, Fairfax, Virginia
Research Site, Chermside, Not set
Research Site, Clayton, Not set
Research Site, Melbourne, Not set
Research Site, Nedlands, Not set
Research Site, Westmead, Not set
Research Site, Anderlecht, Not set
Research Site, Antwerpen, Not set
Research Site, Gent, Not set
Research Site, Hasselt, Not set
Research Site, Leuven, Not set
Research Site, Sint-Niklaas, Not set
Research Site, Barretos, Not set
Research Site, Fortaleza, Not set
Research Site, Joao Pessoa, Not set
Research Site, Porto Alegre, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Santo Andre, Not set
Research Site, São Paulo, Not set
Research Site, Edmonton, Alberta
Research Site, Hamilton, Ontario
Research Site, London, Ontario
Research Site, Ottawa, Ontario
Research Site, Toronto, Ontario
Research Site, Montréal, Quebec
Research Site, Quebec, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Harbin, Not set
Research Site, Kunming, Not set
Research Site, Lanzhou, Not set
Research Site, Nanchang, Not set
Research Site, Ningbo, Not set
Research Site, Qingdao, Not set
Research Site, Shandong, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Taiyuan, Not set
Research Site, Taiyuan, Not set
Research Site, Tianjin, Not set
Research Site, Tianjin, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Zhengzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Aarhus N, Not set
Research Site, Copenhagen, Not set
Research Site, Brest, Not set
Research Site, Creteil Cedex, Not set
Research Site, Le Mans Cedex, Not set
Research Site, Lille, Not set
Research Site, Lyon, Not set
Research Site, Marseille Cedex 20, Not set
Research Site, Montpellier, Not set
Research Site, Paris, Not set
Research Site, Rouen, Not set
Research Site, Saint Herblain, Not set
Research Site, Strasbourg, Not set
Research Site, Toulouse, Not set
Research Site, Berlin, Not set
Research Site, Berlin, Not set
Research Site, Bochum, Not set
Research Site, Essen, Not set
Research Site, Essen, Not set
Research Site, Gauting, Not set
Research Site, Georgsmarienhuette, Not set
Research Site, Grosshansdorf, Not set
Research Site, Hamburg, Not set
Research Site, Heidelberg, Not set
Research Site, Kiel, Not set
Research Site, Köln, Not set
Research Site, Muenster, Not set
Research Site, Regensburg, Not set
Research Site, Alessandria, Not set
Research Site, Bari, Not set
Research Site, Bergamo, Not set
Research Site, Milan, Not set
Research Site, Monza, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Parma, Not set
Research Site, Rozzano, Not set
Research Site, Varese, Not set
Research Site, Amagasaki-shi, Not set
Research Site, Hakodate-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Kitaadachi-gun, Not set
Research Site, Kitakyushu-shi, Not set
Research Site, Matsuyama-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nishinomiya-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Tokyo, Not set
Research Site, Ube-shi, Not set
Research Site, Cheongju-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Ulsan, Not set
Research Site, Amsterdam, Not set
Research Site, Eindhoven, Not set
Research Site, Rotterdam, Not set
Research Site, Lørenskog, Not set
Research Site, Oslo, Not set
Research Site, Bydgoszcz, Not set
Research Site, Bystra, Not set
Research Site, Olsztyn, Not set
Research Site, Poznań, Not set
Research Site, Rzeszów, Not set
Research Site, Warszawa, Not set
Research Site, Amanzimtoti, Not set
Research Site, Cape Town, Not set
Research Site, Johannesburg, Not set
Research Site, Johannesburg, Not set
Research Site, Kimberly, Not set
Research Site, Polokwane, Not set
Research Site, Pretoria, Not set
Research Site, Pretoria, Not set
Research Site, Barakaldo, Not set
Research Site, Barcelona, Not set
Research Site, Madrid, Not set
Research Site, Oviedo, Not set
Research Site, Baden, Not set
Research Site, Basel, Not set
Research Site, Bern, Not set
Research Site, Fribourg, Not set
Research Site, St. Gallen, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Adana, Not set
Research Site, Ankara, Not set
Research Site, Ankara, Not set
Research Site, Diyarbakir, Not set
Research Site, Izmir, Not set
Research Site, Cambridge, Not set
Research Site, Cardiff, Wales, Not set
Research Site, Leeds, Not set
Research Site, Leicester, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Newcastle-upon-Tyne, Not set
Research Site, Portsmouth, Not set
Research Site, Taunton, Not set
Conditions: Unresectable Pleural Mesothelioma
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Recruiting
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Arizona Oncology Associates, PC, Tucson, Arizona +61 locations
Arizona Oncology Associates, PC, Tucson, Arizona
Beverly Hills Cancer Center, Beverly Hills, California
Valkyrie Clinical Trials, Los Angeles, California
Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto, California
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California
Rocky Mountain Cancer Centers (RMCC), Denver, Colorado
Yale University - Yale Cancer Center, New Haven, Connecticut
Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida
Kaiser Permanente - Moanalua Medical Center And Clinic, Honolulu, Hawaii
Orchard Healthcare Research Inc., Skokie, Illinois
Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois
Northwest Cancer Centers, P.C., Dyer, Indiana
Community Health Network, Indianapolis, Indiana
Helen G. Nassif Community Cancer Center, Cedar Rapids, Iowa
Henry Ford Hospital, Detroit, Michigan
HealthPartners Regions Specialty Clinics, Saint Louis Park, Minnesota
Minnesota Oncology - Woodbury Clinic, Woodbury, Minnesota
Bozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana
Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), New Brunswick, New Jersey
Stony Brook University Hospital, Stony Brook, New York
Clinical Research Alliance Inc., Westbury, New York
FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina
The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee
University of Tennessee Medical Center, Knoxville, Tennessee
SCRI Oncology Partners, Nashville, Tennessee
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Ut Health Science Center - San Antonio (UTHSCSA), Cancer Therapy & Research Center, San Antonio, Texas
Bon Secours St. Francis Medical Center, Midlothian, Virginia
Virginia Oncology Associates, Norfolk, Virginia
Northwest Cancer Specialists, Vancouver, Washington
Icon Cancer Care, Wesley Clinic, Auchenflower, Not set
Peninsula Oncology Centre, Frankston, Not set
Peter MacCallum Cancer Centre, Melbourne, Not set
Mater Hospital Sydney, Sydney, Not set
Westmead Hospital, Westmead, Not set
Baskent Universitesi Tip Fakultesi Adana Hastanesi, Adana, Not set
Medical Park Seyhan Hospital, Adana, Not set
Adana City Training and Research Hospital, Adana, Not set
Sakarya University - Faculty of Medicine, Adapazarı, Not set
Gulhane Egitim ve Arastirma Hastanesi, Ankara, Not set
Hacettepe Universitesi Kanser Enstitusu, Ankara, Not set
Sbu Dr.A.Y. Ankara Onkoloji SUAM, Ankara, Not set
Memorial Ankara Hospital, Ankara, Not set
Ankara City Hospital, Ankara, Not set
Gaziantep Sanko University Medical Faculty, Gaziantep, Not set
Koc Universitesi Hastanesi (Koc University Hospital), Istanbul, Not set
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Not set
Istinye Universitesi Bahcesehir Liv Hospital, Istanbul, Not set
Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Not set
Yeditepe University Hospital, Istanbul, Not set
Medical Point Izmir Hospital, İzmir, Not set
Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Not set
Acibadem Adana Hospital, Seyhan, Not set
Gazi University Medical Faculty, Yenimahalle, Not set
Stoke Mandeville Hospital - Buckinghamshire Healthcare NHS Trust, Aylesbury, Not set
Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital, Cottingham, Not set
Edinburgh Cancer Centre-Western General Hospital, Edinburgh, Not set
St James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, Not set
St Bartholomew's Hospital - Barts Health NHS Trust, London, Not set
University College London Hospitals NHS Foundation Trust, London, Not set
Sarah Cannon Research Institute, London, Not set
Nottingham University Hospitals NHS Trust, Nottingham, Not set
Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Recruiting
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib... Read More
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort. Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Call for Information (Investigational Site 0005), Los Angeles, California +26 locations
Call for Information (Investigational Site 0005), Los Angeles, California
Call for Information (Investigational Site 2041), Aurora, Colorado
Call for Information (Investigational Site 2083), Baltimore, Maryland
Call for Information (Investigational Site 2091), Cleveland, Ohio
Call for Information (Investigational Site 2027), Portland, Oregon
Call for Information (Investigational Site 2094), Portland, Oregon
Call for Information (Investigational Site 0008), Pittsburgh, Pennsylvania
Call for Information (Investigational Site 2065), Charleston, South Carolina
Call for Information (Investigational Site 0019), Myrtle Beach, South Carolina
Call for Information (Investigational Site 0016), Seattle, Washington
MSD Australia, North Ryde, Not set
Merck Canada, Kirkland, Quebec
MSD Denmark, Glostrup, Not set
MSD Finland Oy, Espoo, Not set
MSD France, Paris, Not set
MSD Sharp & Dohme GmbH, München, Not set
MSD Ireland (Human Health) Ltd., Dublin, Not set
MSD Italia S.r.l., Rome, Not set
MSD Comercializadora, S. de R.L. de C.V., Mexico City, Not set
Merck Sharp & Dohme BV, Haarlem, Not set
Merck Sharp & Dohme (New Zealand) Ltd.,, Auckland, Not set
MSD Polska Sp. Z o.o., Warsaw, Not set
Merck Sharp and Dohme de Espana S.A., Madrid, Not set
MSD Sweden, Stockholm, Not set
Merck Sharp & Dohme (I.A.) Corp., Taipei, Not set
Merck Sharp & Dohme Ilaclari Ltd. Sti, Istanbul, Not set
Merck Sharp & Dohme Ltd., London, Not set
Conditions: Metastatic Castration-Resistant Prostate Cancer
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Recruiting
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: City of Hope, Duarte, California +41 locations
City of Hope, Duarte, California
City of Hope, Huntington Beach, California
City of Hope, Irvine, California
City of Hope, Long Beach, California
University of California, San Francisco, San Francisco, California
Yale Cancer Center, New Haven, Connecticut
Georgetown University, Washington, District of Columbia
Mayo Clinic, Jacksonville, Florida
Moffitt Cancer Center, Tampa, Florida
Northwestern University, Chicago, Illinois
Dana Farber Cancer Institute, Boston, Massachusetts
Mayo Clinic, Rochester, Minnesota
NYU Langone Health Perlmutter Cancer Center, New York, New York
Duke Cancer Institute, Durham, North Carolina
University of Pennsylvania, Philadelphia, Pennsylvania
Spartanburg Regional Healthcare System, Spartanburg, South Carolina
Next Oncology, Fairfax, Virginia
Chris O'Brien Lifehouse, Camperdown, Not set
Peter MacCallum Cancer Centre, Melbourne, Not set
One Clinical Research, Hollywood Medical Centre, Nedlands, Not set
Sydney Adventist Health, Sydney, Not set
Princess Margaret Cancer Centre, Toronto, Ontario
The Chinese University of Hong Kong, Shatin, Not set
Chungbuk University Hospital, Cheongju-si, Not set
National Cancer Center, Goyang-si, Not set
Catholic University of Korea, St, Vincent Hospital, Gyeonggi-do, Not set
Gachon University Hospital, Incheon, Not set
Seoul National Bundang Hospital, Seongnam-si, Not set
Asan Medical Center, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
Sultan Ahmad Shah Medical Centre at International Islamic University Malaysia (IIUM), Kuantan, Pahang
Pulau Pinang Hospital, George Town, Penang
Sarawak General Hospital (SGH), Kuching, Sarawak
Hospital Kuala Lumpur, Kuala Lumpur, Not set
University of Malaya Medical Center (UMMC), Kuala Lumpur, Not set
Medical University of Gdańsk, Gdańsk, Not set
NEXT Oncology - Barcelona, Barcelona, Not set
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Not set
NEXT Oncology - Madrid, Madrid, Not set
National Taiwan University Hospital, Taipei, Not set
The Christie NHS Foundation Trust, Manchester, England
Conditions: Solid Tumors
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Active Not Recruiting
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizu... Read More
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Alabama Oncology Bruno Cancer Center ( Site 0001), Birmingham, Alabama +177 locations
Alabama Oncology Bruno Cancer Center ( Site 0001), Birmingham, Alabama
Northwest Alabama Cancer Center, PC ( Site 0002), Muscle Shoals, Alabama
Disney Family Cancer Center ( Site 0005), Burbank, California
Boca Raton Regional Hospital ( Site 0018), Boca Raton, Florida
Mid-Florida Cancer Centers ( Site 0022), Orange City, Florida
Moffitt Cancer Center ( Site 0024), Tampa, Florida
Columbus Regional Research Institute ( Site 0098), Columbus, Georgia
Mount Sinai Hospital Medical Center ( Site 0032), Chicago, Illinois
Oncology of Northshore ( Site 0033), Rolling Meadows, Illinois
Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036), Merrillville, Indiana
Medstar Good Samaritan Hospital ( Site 0040), Baltimore, Maryland
Barbara Ann Karmanos Cancer Institute ( Site 0041), Detroit, Michigan
Hattiesburg Clinic ( Site 0045), Hattiesburg, Mississippi
Frontier Oncology ( Site 0080), Billings, Montana
Bozeman Health Deaconness Cancer Center ( Site 0046), Bozeman, Montana
Waverly Hematology Oncology ( Site 0081), Cary, North Carolina
Thompson Cancer Survival Center ( Site 2812), Knoxville, Tennessee
University of Tennessee Medical Center Knoxville ( Site 0060), Knoxville, Tennessee
Renovatio Clinical ( Site 0062), The Woodlands, Texas
Cancer Care Northwest ( Site 0071), Spokane Valley, Washington
Hospital Italiano Regional del Sur ( Site 0509), Bahia Blanca, Buenos Aires
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511), Ciudad Autonoma de Buenos Aires, Buenos Aires
Hospital Britanico de Buenos Aires ( Site 0500), Ciudad autónoma de Buenos Aires, Buenos Aires
Instituto Medico Rio Cuarto ( Site 0501), Rio Cuarto., Cordoba
Centro Oncológico de Rosario ( Site 0507), Rosario, Santa Fe
Centro Medico San Roque ( Site 0506), San Miguel de Tucuman, Tucuman
Clínica Universitaria Reina Fabiola ( Site 0505), Cordoba, Not set
Sanatorio Privado San Geronimo S.R.L ( Site 0510), Santa Fe, Not set
Liverpool Hospital ( Site 1201), Liverpool, New South Wales
Southern Medical Day Care Centre ( Site 1200), Wollongong, New South Wales
Townsville General Hospital ( Site 1202), Townsville, Queensland
Monash Cancer Centre ( Site 1205), Clayton, Victoria
Ordensklinikum Linz GmbH Elisabethinen ( Site 1307), Linz, Oberosterreich
Klinikum Wels-Grieskirchen ( Site 1304), Wels, Oberosterreich
Innsbruck LKH ( Site 1302), Innsbruck, Tirol
Social Medical Center - Otto Wagner Hospital ( Site 1301), Vienna, Wien
Krankenhaus Nord - Klinik Floridsdorf ( Site 1300), Wien, Not set
Hospital Sao Rafael ( Site 0212), Salvador, Bahia
Instituto do Cancer do Ceara ( Site 0201), Fortaleza, Ceara
Oncologica do Brasil ( Site 0210), Belem, Para
Hospital Tacchini ( Site 0208), Bento Goncalves, Rio Grande Do Sul
Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0209), Porto Alegre, Rio Grande Do Sul
Saint Gallen Instituto de Oncologia ( Site 0206), Santa Cruz do Sul, Rio Grande Do Sul
YNOVA Pesquisa Clinica ( Site 0215), Florianopolis, Santa Catarina
Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0202), Itajai, Santa Catarina
Centro de Hematologia e Oncologia ( Site 0205), Joinville, Santa Catarina
Hospital de Base de Sao Jose de Rio Preto ( Site 0204), Sao Jose Rio Preto, Sao Paulo
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203), Rio de Janeiro, Not set
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200), Sao Paulo, Not set
BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214), Sao Paulo, Not set
Hospital Paulistano - Amil Clinical Research ( Site 0207), Sao Paulo, Not set
Lions Gate Hospital ( Site 0106), North Vancouver, British Columbia
BC Cancer - Victoria ( Site 0109), Victoria, British Columbia
Queen Elizabeth II Health Sciences Centre ( Site 0107), Halifax, Nova Scotia
Waterloo Regional Health Network (WRHN) ( Site 0117), Kitchener, Ontario
Stronach Regional Cancer Centre ( Site 0101), Newmarket, Ontario
Health Sciences North Research Institute ( Site 0115), Sudbury, Ontario
CISSS de la Monteregie-Centre ( Site 0114), Greenfield Park, Quebec
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0105), Montreal, Quebec
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0110), Montreal, Quebec
Centre de Sante et des Services Sociaux de Rimouski-Neigette ( Site 0104), Rimouski, Quebec
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103), Sherbrooke, Quebec
Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0604), Medellin, Antioquia
Clinica de la Costa S.A.S. ( Site 0608), Barranquilla, Atlantico
Administradora Country S.A. ( Site 0603), Bogota, Distrito Capital De Bogota
Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0601), Bogotá, Distrito Capital De Bogota
Institut De Cancerologie De Lorraine ( Site 1409), Vandoeuvre les Nancy, Ain
Centre Hospitalier De Chauny ( Site 1411), Chauny, Aisne
CHU Caen ( Site 1406), Caen, Calvados
CHU Angers ( Site 1405), Angers, Maine-et-Loire
Hopital Robert Schuman ( Site 1402), Vantoux, Moselle
Centre Jean Perrin ( Site 1407), Clermont Ferrand, Puy-de-Dome
Centre Hospitalier de Pau ( Site 1412), Pau, Pyrenees-Atlantiques
CHU de Rouen ( Site 1403), Rouen, Seine-Maritime
Hopital d'Instruction des Armees Begin ( Site 1413), Saint-Mande, Val-de-Marne
Studienzentrum Aschaffenburg ( Site 1525), Aschaffenburg, Bayern
Klinikum Bogenhausen Staedt. Klinikum Muenchen GmbH ( Site 1523), Muenchen, Bayern
Klinikum der LMU ( Site 1500), Munich, Bayern
Universitaetsklinikum Regensburg ( Site 1512), Regensburg, Bayern
Klinikum Wuerzburg Mitte gGmbH ( Site 1509), Wuerzburg, Bayern
Universitaetsklinikum Frankfurt ( Site 1513), Frankfurt, Hessen
Pneumologische Lehrklinik Universitaet Goettingen ( Site 1501), Immenhausen, Hessen
Universitaetsmedizin Goettingen ( Site 1507), Goettingen, Niedersachsen
Universitaetsklinikum Bonn ( Site 1524), Bonn, Nordrhein-Westfalen
Kliniken Essen Mitte ( Site 1517), Essen, Nordrhein-Westfalen
InVo-Institut fuer Versorgungsforschung in der Onkologie ( Site 1514), Koblenz, Rheinland-Pfalz
Helios Klinikum Erfurt GmbH ( Site 1502), Erfurt, Thuringen
Katholisches Marienkrankenhaus gGmbH ( Site 1522), Hamburg, Not set
National Hospital Organization Nagoya Medical Center ( Site 0806), Nagoya, Aichi
Aichi Cancer Center ( Site 0803), Nagoya, Aichi
National Cancer Center Hospital East ( Site 0801), Kashiwa, Chiba
Kanazawa University Hospital ( Site 0811), Kanazawa, Ishikawa
Kanagawa Cancer Center ( Site 0807), Yokohama, Kanagawa
Sendai Kousei Hospital ( Site 0812), Sendai, Miyagi
Kansai Medical University Hospital ( Site 0804), Hirakata, Osaka
National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0813), Sakai, Osaka
Shizuoka Cancer Center ( Site 0802), Suntogun, Shizuoka
National Hospital Organization Kyushu Medical Center ( Site 0805), Fukuoka, Not set
Niigata Cancer Center Hospital ( Site 0808), Niigata, Not set
Okayama University Hospital ( Site 0810), Okayama, Not set
Osaka International Cancer Institute ( Site 0809), Osaka, Not set
Cancer Institute Hospital of JFCR ( Site 0800), Tokyo, Not set
Chungbuk National University Hospital ( Site 1002), Cheongju si, Chungbuk
National Cancer Center ( Site 1006), Goyang-si, Kyonggi-do
The Catholic University of Korea St. Vincent s Hospital ( Site 1003), Suwon, Kyonggi-do
Ajou University Hospital ( Site 1004), Suwon, Kyonggi-do
Gyeongsang National University Hospital ( Site 1005), Jinju, Kyongsangnam-do
Asan Medical Center ( Site 1007), Songpa-gu, Seoul
Seoul National University Hospital ( Site 1000), Seoul, Not set
Korea University Guro Hospital ( Site 1008), Seoul, Not set
MidCentral DHB Palmerston North Hospital ( Site 1102), Palmerston North, Manawatu-Wanganui
Capital & Coast District Health Board - Wellington Hospital ( Site 1101), Wellington, Not set
Wielospecjalistyczny Szpital SPZOZ w Zgorzelcu ( Site 2404), Zgorzelec, Dolnoslaskie
Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2420), Krakow, Malopolskie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2418), Warszawa, Mazowieckie
Szpital Rejonowy im. dr Jozefa Rostka ( Site 2402), Raciborz, Slaskie
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 2417), Olsztyn, Warminsko-mazurskie
Przychodnia Lekarska Komed ( Site 2416), Konin, Wielkopolskie
MED-POLONIA Sp. z o.o. ( Site 2419), Poznan, Wielkopolskie
MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2502), Bucharest, Bucuresti
Cardiomed SRL Cluj-Napoca ( Site 2504), Cluj Napoca, Cluj
S.C. Radiotherapy Center Cluj S.R.L ( Site 2507), Cluj-Napoca, Cluj
Ovidius Clinical Hospital OCH ( Site 2501), Ovidiu, Constanta
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2508), Craiova, Dolj
Policlinica Oncomed SRL ( Site 2505), Timisoara, Timis
Spitalul PDR Medlife ( Site 2509), Brasov, Not set
Moscow Regional Oncological Dispensary ( Site 2028), Balashikha, Moskovskaya Oblast
Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 2000), Moscow, Moskva
First Moscow State Medical University n.a. I.M.Sechenov ( Site 2024), Moscow, Moskva
Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2009), Moscow, Moskva
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 2006), Moscow, Moskva
Nizhniy Novgorod Region Oncology Dispensary ( Site 2026), Nizhniy Novgorod, Nizhegorodskaya Oblast
Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site 2010), Omsk, Omskaya Oblast
SBHI Samara Regional Clinical Oncology Dispensary ( Site 2016), Samara, Samarskaya Oblast
SBHI Leningrad Regional Clinical Hospital ( Site 2002), Saint Petersburg, Sankt-Peterburg
SPb Central Clinical Railway Hospital ( Site 2003), Saint Petersburg, Sankt-Peterburg
National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 2004), Saint Petersburg, Sankt-Peterburg
SPb SBHI City Clinical Oncological Dispensary ( Site 2001), Saint Petersburg, Sankt-Peterburg
Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2021), Kazan, Tatarstan, Respublika
Hospital Universitario Quiron Madrid ( Site 1701), Pozuelo de Alarcon, Madrid
Hospital Clinico Universitario de Valencia ( Site 1706), Valencia, Valenciana, Comunitat
Hospital del Mar ( Site 1702), Barcelona, Not set
Hospital Universitario Nuestra Senora de Valme ( Site 1703), Sevilla, Not set
Hospital Clinico Lozano Blesa ( Site 1700), Zaragoza, Not set
Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0907), Kaohsiung, Not set
China Medical University Hospital ( Site 0904), Taichung, Not set
National Cheng Kung University Hospital ( Site 0905), Tainan, Not set
National Taiwan University Hospital ( Site 0900), Taipei, Not set
Mackay Memorial Hospital ( Site 0902), Taipei, Not set
Chang Gung Medical Foundation.Linkou Branch ( Site 0903), Taoyuan, Not set
Namik Kemal Universitesi Tip Fakultesi ( Site 2100), Tekirdag, Tekirdas
Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 2101), Adana, Not set
Gazi Universitesi Tip Fakultesi ( Site 2104), Ankara, Not set
Ankara Bilkent Sehir Hastanesi ( Site 2105), Ankara, Not set
Bezmialem Vakif Univ. Tıp Fakultesi Hastanesi Tibbi Onkoloji Bolumu ( Site 2107), Istanbul, Not set
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2103), Istanbul, Not set
Ege Universitesi Tip Fakultesi ( Site 2109), Izmir, Not set
Erciyes Universitesi Tip Fakultesi ( Site 2108), Kayseri, Not set
Ondokuz Mayıs Universitesi-Oncology department ( Site 2106), Samsun, Not set
Cherkasy Regional Oncology Dispensary ( Site 2211), Cherkasy, Cherkaska Oblast
Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 2201), Dnipro, Dnipropetrovska Oblast
MI Precarpathian Clinical Oncology Center ( Site 2204), Ivano-Frankivsk, Ivano-Frankivska Oblast
Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2212), Kharkiv, Kharkivska Oblast
CNPE "Regional Center of Oncology"-Thoracic organs ( Site 2205), Kharkiv, Kharkivska Oblast
PP PPC Acinus Medical and Diagnostic Centre ( Site 2209), Kropyvnitskiy, Kirovohradska Oblast
Medical Center Asklepion LLC ( Site 2234), Khodosivka, Kyivska Oblast
Medical Center Verum ( Site 2230), Kyiv, Kyivska Oblast
Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2213), Kyiv, Kyivska Oblast
MI Odessa Regional Oncological Centre ( Site 2208), Odesa, Odeska Oblast
Central City Clinical Hospital ( Site 2207), Uzhgorod, Zakarpatska Oblast
Kyiv City Clinical Oncology Centre ( Site 2210), Kyiv, Not set
Barts Health NHS Trust - St Bartholomew s Hospital ( Site 1923), London, London, City Of
Chelsea and Westminster Hospital ( Site 1901), London, London, City Of
West Suffolk Hospitals NHS Trust ( Site 1919), Bury Saint Edmunds, Suffolk
Singleton Hospital ( Site 1909), Swansea, Wales
Colchester General Hospital ( Site 1911), Colchester, Worcestershire
Birmingham Heartlands Hospital ( Site 1910), Birmingham, Not set
Western General Hospital, Edinburgh ( Site 1924), Edinburg, Not set
Conditions: Carcinoma, Nonsquamous Non-small-cell Lung
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Active Not Recruiting
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Hoag Hospital, Irvine, California +43 locations
Hoag Hospital, Irvine, California
University of California San Diego, La Jolla, California
Cedar Sinai Medical Center, Los Angeles, California
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida
Moffitt Cancer Center, Tampa, Florida
Rush University Medical Center, Chicago, Illinois
University of Louisville, Louisville, Kentucky
University of Maryland Medical System, Baltimore, Maryland
Memorial Sloan Kettering, New York, New York
The Ohio State University, Columbus, Ohio
Oregon Health & Science University/ Knight Cancer Institute, Portland, Oregon
Vanderbilt - Ingram Cancer Center, Nashville, Tennessee
Houston Methodist Cancer Center, Houston, Texas
Royal Brisbane and Womens Hospital, Herston, Queensland
Ashford Cancer Centre, Adelaide, South Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria
Sir Charles Gairdner Hospital, Nedlands, Not set
Cliniques Universitaires Saint-Luc, Bruxelles, Not set
AZ Groeninge, Kortrijk, Not set
Chungbuk National University Hospital, Cheongju-si, Not set
Yeungnam University Medical Center, Daegu, Not set
Gachon University (GCU) - Gil Medical Center (Gil Hospital), Incheon, Not set
CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center), Seongnam-si, Not set
Seoul National University, Bundang Hospital, Seongnam, Not set
The Catholic University of Korea - Eunpyeong St. Mary's Hospital, Seoul, Not set
Seoul National University Hospital (SNUH) - SMG-SNU Boramae Medical Center, Seoul, Not set
Seoul National University Hospital, Seoul, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Amsterdam UMC, Locatie VUMC, Amsterdam, Not set
Universitair Medisch Centrum Groningen, Groningen, Not set
National University Cancer Institute, Singapore, Not set
National Cancer Centre Singapore, Singapore, Not set
Institut Catala d Oncologia (ICO), Badalona, Not set
Hospital Universitari Dexeus, Barcelona, Not set
Institut Catala dOncologia, L'Hospitalet De Llobregat, Not set
Hospital Universitario Severo Ochoa, Leganés, Not set
Grupo Hospital de Madrid (HM) - Hospital Universitario Madrid Sanchinarro - Cent, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital Regional Universitario de Malaga, Málaga, Not set
Hospital Universitario de Navarra, Pamplona, Not set
The Royal Marsden Hospital - Surrey, London, Not set
University College London Hospital, London, Not set
The Royal Marsden Hospital- London, London, Not set
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Tucson, Arizona +290 locations
Research Site, Tucson, Arizona
Research Site, Springdale, Arkansas
Research Site, Beverly Hills, California
Research Site, Glendale, California
Research Site, Los Alamitos, California
Research Site, Redlands, California
Research Site, San Francisco, California
Research Site, Walnut Creek, California
Research Site, West Haven, Connecticut
Research Site, Newark, Delaware
Research Site, Bay Pines, Florida
Research Site, Fort Lauderdale, Florida
Research Site, Gainesville, Florida
Research Site, Gainesville, Florida
Research Site, Jacksonville, Florida
Research Site, Athens, Georgia
Research Site, Atlanta, Georgia
Research Site, Boise, Idaho
Research Site, Chicago, Illinois
Research Site, Decatur, Illinois
Research Site, Hinsdale, Illinois
Research Site, Quincy, Illinois
Research Site, Waterloo, Iowa
Research Site, Lexington, Kentucky
Research Site, Lexington, Kentucky
Research Site, Louisville, Kentucky
Research Site, Louisville, Kentucky
Research Site, Alexandria, Louisiana
Research Site, Baton Rouge, Louisiana
Research Site, Covington, Louisiana
Research Site, Shreveport, Louisiana
Research Site, Shreveport, Louisiana
Research Site, South Portland, Maine
Research Site, Baltimore, Maryland
Research Site, Bethesda, Maryland
Research Site, Detroit, Michigan
Research Site, Grand Rapids, Michigan
Research Site, Duluth, Minnesota
Research Site, Rochester, Minnesota
Research Site, Bridgeton, Missouri
Research Site, Columbia, Missouri
Research Site, Kansas City, Missouri
Research Site, Lincoln, Nebraska
Research Site, Camden, New Jersey
Research Site, Buffalo, New York
Research Site, East Syracuse, New York
Research Site, Westbury, New York
Research Site, Cincinnati, Ohio
Research Site, Bend, Oregon
Research Site, Medford, Oregon
Research Site, Salem, Oregon
Research Site, Hershey, Pennsylvania
Research Site, York, Pennsylvania
Research Site, Sioux Falls, South Dakota
Research Site, Chattanooga, Tennessee
Research Site, Nashville, Tennessee
Research Site, Fort Worth, Texas
Research Site, Houston, Texas
Research Site, Kingwood, Texas
Research Site, Lubbock, Texas
Research Site, Round Rock, Texas
Research Site, Fairfax, Virginia
Research Site, Fredericksburg, Virginia
Research Site, Olympia, Washington
Research Site, Seattle, Washington
Research Site, Silverdale, Washington
Research Site, Spokane, Washington
Research Site, Tacoma, Washington
Research Site, Wenatchee, Washington
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, La Plata, Not set
Research Site, Pilar, Not set
Research Site, Rosario, Not set
Research Site, Darlinghurst, Not set
Research Site, Hyde Park, Not set
Research Site, Southport, Not set
Research Site, Wollongong, Not set
Research Site, Innsbruck, Not set
Research Site, Krems, Not set
Research Site, Rankweil, Not set
Research Site, Wien, Not set
Research Site, Wien, Not set
Research Site, Anderlecht, Not set
Research Site, Brussels, Not set
Research Site, Charleroi, Not set
Research Site, Kortrijk, Not set
Research Site, Ottignies, Not set
Research Site, Sint-Niklaas, Not set
Research Site, Barretos, Not set
Research Site, Florianópolis, Not set
Research Site, Ijuí, Not set
Research Site, Londrina, Not set
Research Site, Porto Alegre, Not set
Research Site, Salvador, Not set
Research Site, Sao Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Taubaté, Not set
Research Site, Saint John, New Brunswick
Research Site, Sydney, Nova Scotia
Research Site, Hamilton, Ontario
Research Site, Sault Ste. Marie, Ontario
Research Site, Montréal, Quebec
Research Site, Montréal, Quebec
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changde, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Dalian, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Harbin, Not set
Research Site, Hefei, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Kunming, Not set
Research Site, Linhai, Not set
Research Site, Linyi, Not set
Research Site, Nanchang, Not set
Research Site, Ningbo, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Shenzhen, Not set
Research Site, Taiyuan, Not set
Research Site, Tianjin, Not set
Research Site, Wenzhou, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Yangzhou, Not set
Research Site, Yueyang, Not set
Research Site, Zhengzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Avignon, Not set
Research Site, La Rochelle Cedex, Not set
Research Site, Lyon, Not set
Research Site, Nimes, Not set
Research Site, Rennes, Not set
Research Site, Strasbourg Cedex, Not set
Research Site, Suresnes, Not set
Research Site, Toulon Cedex 9, Not set
Research Site, Bad Berka, Not set
Research Site, Berlin, Not set
Research Site, Berlin, Not set
Research Site, Esslingen, Not set
Research Site, Frankfurt, Not set
Research Site, Gauting, Not set
Research Site, Gießen, Not set
Research Site, Großhansdorf, Not set
Research Site, Hamburg, Not set
Research Site, Hannover, Not set
Research Site, Hannover, Not set
Research Site, Heidelberg, Not set
Research Site, Hemer, Not set
Research Site, Homburg, Not set
Research Site, Kassel, Not set
Research Site, Kiel, Not set
Research Site, Krefeld, Not set
Research Site, Köln, Not set
Research Site, Minden, Not set
Research Site, Moers, Not set
Research Site, München, Not set
Research Site, Regensburg, Not set
Research Site, Würzburg, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Debrecen, Not set
Research Site, Gyöngyös, Not set
Research Site, Győr, Not set
Research Site, Pécs, Not set
Research Site, Székesfehérvár, Not set
Research Site, Törökbálint, Not set
Research Site, Calicut, Not set
Research Site, Delhi, Not set
Research Site, Kolkata, Not set
Research Site, Madurai, Not set
Research Site, Mumbai, Not set
Research Site, Nashik, Not set
Research Site, New Delhi, Not set
Research Site, Pondicherry, Not set
Research Site, Surat, Not set
Research Site, Varanasi, Not set
Research Site, Firenze, Not set
Research Site, Monza, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Peschiera Del Garda, Not set
Research Site, Roma, Not set
Research Site, Amagasaki-shi, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Kawagoe-shi, Not set
Research Site, Kitaadachi-gun, Not set
Research Site, Kitakyushu-shi, Not set
Research Site, Kobe-shi, Not set
Research Site, Koto-ku, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Matsusaka-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama, Not set
Research Site, Ota-shi, Not set
Research Site, Saitama-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Shinjuku-ku, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Cheongju-si, Not set
Research Site, Incheon, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon-si, Not set
Research Site, Suwon-si, Not set
Research Site, George Town, Not set
Research Site, Johor Bahru, Not set
Research Site, Kuala Lumpur, Not set
Research Site, Alkmaar, Not set
Research Site, Ede, Not set
Research Site, Groningen, Not set
Research Site, Leidschendam, Not set
Research Site, Veldhoven, Not set
Research Site, Zwolle, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Biała Podlaska, Not set
Research Site, Białystok, Not set
Research Site, Bydgoszcz, Not set
Research Site, Bystra, Not set
Research Site, Poznań, Not set
Research Site, Warszawa, Not set
Research Site, Łódź, Not set
Research Site, San Juan, Not set
Research Site, San Juan, Not set
Research Site, Barcelona, Not set
Research Site, Las Palmas de Gran Canaria, Not set
Research Site, Lérida, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Majadahonda, Not set
Research Site, Sevilla, Not set
Research Site, Kaohsiung, Not set
Research Site, Kaohsiung, Not set
Research Site, New Taipei, Not set
Research Site, New Taipei, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taoyuan, Not set
Research Site, Bangkok, Not set
Research Site, Chiang Mai, Not set
Research Site, Dusit, Not set
Research Site, Nakhon Ratchasima, Not set
Research Site, Songkla, Not set
Research Site, Antalya, Not set
Research Site, İstanbul, Not set
Research Site, Yenimahalle, Not set
Research Site, Aberdeen, Not set
Research Site, Cambridge, Not set
Research Site, Edinburgh, Not set
Research Site, Exeter, Not set
Research Site, Greater London, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Newcastle upon Tyne, Not set
Research Site, Preston, Not set
Research Site, Can Tho, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh City, Not set
Research Site, Ho Chi Minh, Not set
Research Site, Vinh, Not set
Conditions: Non-small Cell Lung Cancer
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division.
The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC.
The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations.
The study participants will receive one of the study treatments:
* BAY 2927088 twice every day as a tablet by mouth, or
* Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment.
During the study, the doctors and their study team will:
* take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer
* check the overall health of the participants by performing tests such as blood and urine tests, and checking
* heart health using an electrocardiogram (ECG)
* perform pregnancy tests for women
* ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Patty & George Hoag Cancer Center, Newport Beach, California +278 locations
Patty & George Hoag Cancer Center, Newport Beach, California
UC San Diego Health - Moores Cancer Center, San Diego, California
UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology, San Francisco, California
UCLA Health Santa Monica Cancer Care, Santa Monica, California
The Oncology Institute of Hope and Innovation - Fort Lauderdale 17th Street, Fort Lauderdale, Florida
Memorial Cancer Institute at Miramar, Miramar, Florida
AdventHealth Cancer Institute, Orlando, Florida
Moffitt Cancer Center - Magnolia Campus, Tampa, Florida
Moffitt Cancer Center, Tampa, Florida
Piedmont Cancer Institute - Atlanta, Atlanta, Georgia
John B. Amos Cancer Center, Columbus, Georgia
University of Illinois Hospital - Outpatient Cancer Care Center, Chicago, Illinois
The University of Chicago Medical Center - Hyde Park - Hematology & Oncology, Chicago, Illinois
UM Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
UMass Memorial Medical Center - University Campus - Oncology, Worcester, Massachusetts
Profound Research -OMG - TriAtria Cancer Center, Farmington Hills, Michigan
Profound Research - OMG - Royal Oak Cancer Center, Royal Oak, Michigan
University of Minnesota Medical Center, Minneapolis, Minnesota
R.J. Zuckerberg Cancer Center, New Hyde Park, New York
UC Medical Center - Oncology, Cincinnati, Ohio
Providence Cancer Institute - Franz Clinic, Portland, Oregon
Providence Oncology and Hematology Care Clinic Westside, Portland, Oregon
Allegheny General Hospital, Pittsburgh, Pennsylvania
UT Southwestern, Dallas, Texas
University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas
Virginia Commonwealth University, Richmond, Virginia
Fundación Cenit para la Investigación en Neurociencias, Caba, Ciudad Auton. De Buenos Aires
Hospital Italiano de Buenos Aires, Buenos Aires, Not set
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC), Buenos Aires, Not set
Centro Médico Privado CEMAIC, Córdoba, Not set
Instituto Argentino de Diagnostico y Tratamiento (IADT), TBC, Not set
Centro de Investigaciones Clínicas, Clínica Viedma, Viedma, Not set
Blacktown Cancer & Haematology Centre, Blacktown, New South Wales
Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit, Concord, New South Wales
Calvary Mater Hospital Newcastle, Waratah, New South Wales
University of the Sunshine Coast, Buderim, Not set
The Canberra Hospital (TCH) - Canberra Region Cancer Centre (CRCC), Garran, Not set
Austin Hospital - Olivia Newton John Cancer Research Institute, Heidelberg, Not set
Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III, Salzburg, Not set
Uniklinikum Salzburg, Universitätsklinik für Pneumologie/ Lungenheilkunde, Salzburg, Not set
Medizinische Universität Wien Universitätsklinik f. Innere Medizin I Klinische Abteilung für Onkologie, Wien, Not set
Klinik Floridsdorf, Pneumo-onkologische Ambulanz und Tagesklinik, Wien, Not set
UZ Leuven Gasthuisberg - Pneumology Department, Leuven, Vlaams-Brabant
AZ Delta | Clinical Trial Center - Pneumology, Roeselare, West-Flanders
Antwerp University Hospital | Oncology Department, Antwerpen, Not set
Rede DoR Recife - PE, Recife, Pernambuco
Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica, Natal, Rio Grande Do Norte
Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology, Porto Alegre, Rio Grande Do Sul
Centro de Pesquisa da Clínica de Oncologia Reichow, Blumenau, Santa Catarina
Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, Sao Paulo
Hospital de Base | Integrated Research Center, São José do Rio Preto, Sao Paulo
NAIC - Instituto do Cancer, Bauru, Not set
Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia, Brasilia, Not set
Pronutrir Fortaleza - CE, Fortaleza, Not set
Hospital Sirio Libanes, Sao Paulo, Not set
A Beneficencia Portuguesa de Sao Paulo - Hospital BP Mirante, Sao Paulo, Not set
Centro Paulista de Oncologia (CPO) - Sao Paulo - Faria Lima, Sao Paulo, Not set
MHAT Uni Hospital, Panagyurishte, Pazardzhik
MHAT "Heart and brain" Pleven, Pleven, Not set
Complex Oncology Center - Plovdiv EOOD, Plovdiv, Not set
MHAT Park Hospital EOOD, Plovdiv, Not set
Multiprofile Hospital for Active Treatment "Sveta Sofia", Sofia, Not set
MHAT Serdika, Sofia, Not set
Specialized Hospital for Active Treatment of Oncology, Sofia, Not set
University Multiprofile Hospital For Active Treatment Sofiamed OOD, Sofia, Sofia, Not set
MHAT Sveta Marina EAD, Varna, Not set
BC Cancer - Vancouver Site, Vancouver, British Columbia
Brampton Civic Hospital - Oncology, Brampton, Ontario
Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology, Toronto, Ontario
Jewish General Hospital - Department of Pulmonary Oncology, Montreal, Quebec
Beijing Cancer Hospital - Oncology Department, Beijing, Beijing
Beijing Hospital, Beijing, Beijing
Fujian Cancer Hospital, Fuzhou, Fujian
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang
Union Hospi, Tongji Med College, Huazhong Univ. Scien&Tech, Wuhan, Hubei
Hubei Cancer Hospital, Wuhan, Hubei
Hunan Cancer Hospital - Oncology Department, Changsha, Hunan
NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu
Jilin Cancer Hospital, Changchun, Jilin
Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, Shanghai
West China Hospital Sichuan University, Chengdu, Sichuan
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department, Hangzhou, Zhejiang
Zhejiang Cancer Hospital, Hangzhou, Zhejiang
Zhejiang University School of Medicine - Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Not set
The People's Liberation Army General Hospital (Beijing 301 Hospital), Beijing, Not set
Beijing chest hospital, Capital Medical University, Beijing, Not set
University of Electronic Science & Technology of China - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital), Chengdu, Not set
Guangzhou Medical University - The First Affiliated Hospital, Guangzhou, Not set
Shandong University - Shandong Cancer Hospital, Jinan, Not set
LinYi Cancer Hospital (Linyi Tumor Hospital), Linyi, Not set
Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University, Nanjing, Not set
Guangxi Medical University (GXMU) - Affiliated Tumor Hospital, Nanning, Not set
Zhongshan Hospital, Fudan University - Oncology Department, Shanghai, Not set
Xiamen University - The First Affiliated Hospital, Xiamen, Not set
Krajská nemocnice T. Bati - Pneumoonkologická a klinická onkologie, Zlin, Zlinsky Kraj
Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP), Brno, Not set
Nemocnice AGEL Nový Jicín a.s. - Oddelení radioterapie a onkologie, Nový Jicín, Not set
Fakultní Nemocnice Olomouc - Klinika plicních nemocí a tuberkulózy, Olomouc, Not set
Nemocnice AGEL Ostrava-Vítkovice a. s. - Plicní oddelení, Ostrava - Vítkovice, Not set
Aalborg University hospital - oncology department, Aalborg, Not set
Aarhus Universitetshospital, Aarhus N, Not set
Rigshospitalet - Kræftbehandling, Copenhagen OE, Not set
Regionshospitalet Gødstrup - Medicinsk afdeling, Herning, Not set
Odense University Hospital - Oncology Department, Odense C, Not set
Docrates Mehiläinen Syöpäsairaala, Helsinki, Not set
Turun yliopistollinen keskussairaala, Turku, Not set
Institut Bergonie - Unicancer Nouvelle Aquitaine, Bordeaux, Not set
Hopital La Cavale Blanche - CHU de Brest - institut de cancerologie et d'imagerie, Brest, Not set
Centre Hospitalier Intercommunal Creteil - Service de pneumologie, Créteil, Not set
Centre Hospitalier Michallon Grenoble - Service pneumologie, La Tronche, Not set
Institut Coeur Poumon CHRU Lille - Pole Cardio-vasculaire et pulmonaire, Lille, Not set
Centre Hospitalier Universitaire de Limoges - unite oncologie thoracique, Limoges, Not set
CHU Montpellier - Hopital Arnaud de Villeneuve - Service oncologie thoracique, Montpellier, Not set
hopital Emile Muller - Service Pneumologie, Mulhouse, Not set
Hopital Nord Laennec - Oncologie medicale thoracique et digestive, Nantes, Not set
Centre Antoine Lacassagne - Departement Oncologie, Nice, Not set
hopital cochin APHP - service de pneumologie, Paris, Not set
Institut Curie - Paris - Oncologie medicale, Paris, Not set
hopital Lyon sud HCL - Pneumologie aigue specialisee et cancerologie thoracique, Pierre Bénite, Not set
CHU de Rouen - Hopital Charles Nicolle - Service de Pneumologie, Rouen, Not set
Institut de Cancerologie Ouest - Saint-Herblain, Saint-Herblain, Not set
Hopital Foch - Oncologie digestive et thoracique, Suresnes, Not set
Gustave Roussy - Departement Oncologie-Radiotherapie, Villejuif, Not set
Universitaetsklinikum Giessen und Marburg - Medizinische Klinik IV Organonkologie, Giessen, Hessen
Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik, Köln, Nordrhein-Westfalen
Universitaetsklinikum Essen - Innere Klinik (Tumorforschung), Essen, North Rhine-Westphalia
Charité Universitätsmedizin Berlin CBF - Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Berlin, Not set
Universitätsklinikum Frankfurt - Medizinische Klinik II, Hämatologie und Onkologie, Frankfurt, Not set
Lungenklinik Hemer, Thorakale Onkologie und onkologische Palliativmedizin, Hemer, Not set
Klinikum Nürnberg - Klinik für Innere Medizin 3, Schwerpunkt Pneumologie (Lungenheilkunde), Nürnberg, Not set
Robert Bosch Krankenhaus - Haematologie, Onkologie und Palliativmedizin, Stuttgart, Not set
?enry Durant Hospital Center-4th Oncology Department and Clinical Trials Unit, Athens, Not set
University of Athens Medical School-Sotiria General Hospital - 3rd Dept of Medicine & Medical Oncology, Athens, Not set
General Hospital of Athens "Alexandra''-Plasma Cell Dyscrasias,Department of Clinical Therapeutics,School of Medicine,NKUA, Athens, Not set
University General Hospital ATTIKON, Department of Internal Medicine IV, Chaidari, Not set
University General Hospital of Athens "ATTIKON", Chaidari, Not set
University General Hospital of Larissa, Larissa, Not set
Metropolitan Hospital- 4th Oncology Clinic, Piraeus, Not set
Bioclinic Thessaloniki, Thessaloniki, Not set
PAPANIKOLAOU General Hospital of Thessaloniki, Thessaloniki, Not set
Prince of Wales Hospital, Hong Kong, Not set
Queen Mary Hospital, Hong Kong, Not set
Queen Elizabeth Hospital Hong Kong, Hong Kong, Not set
Hong Kong United Oncology Centre, Kowloon, Not set
Budapesti Uzsoki Utcai Korhaz - Tüdogyógyászati Osztály, Budapest, Not set
Komarom-Esztergom Varmegyei Szent Borbala Korhaz, Tatabanya, Not set
Assuta Ashdod Public Hospital (R.A), Ashdod, Not set
Soroka Medical Center- Legacy Heritage Cancer Center, Be'er Sheva, Not set
Shaare Zedek Medical Center (SZMC), Jerusalem, Not set
Tel-Aviv Sourasky Medical Center, Tel Aviv, Not set
AORN San Giuseppe Moscati Avellino - U.O.C. Oncologia Medica, Avellino, Campania
Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - UOC Oncologia Medica, Bologna, Emilia-Romagna
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. - GDP Toracica, Meldola, Emilia-Romagna
Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati, Aviano, Friuli-Venezia Giulia
I.F.O. Istituti Fisioterapici Ospitalieri_Ospedale Regina Elena -- Oncologia Medica 2, Roma, Lazio
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Oncologia Toraco-Polmonare, Roma, Lazio
Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1, Milano, Lombardia
Istituto Europeo di Oncologia s.r.l - Oncologia Toracica, Milano, Lombardia
Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia, Rozzano, Lombardia
Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica, Orbassano, Piemonte
Istituto Oncologico Veneto_Padova - UOC Oncologia 2, Padova, Veneto
Careggi University Hospital - Oncologia Clinica, Firenze, Not set
Careggi University Hospital - Oncologia Clinica, Firenze, Not set
Ospedale Vito Fazzi Lecce - Oncologia, Lecce, Not set
Ospedale San Raffaele s.r.l. - Oncologia Medica, Milano, Not set
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello - Oncologia Medica, Palermo, Not set
ASST Sette Laghi_Ospedale Macchi - Oncologia, Varese, Not set
Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia, Verona, Not set
National Hospital Organization Nagoya Medical Center, Nagoya, Aichi
National Cancer Center Hospital East, Kashiwa, Chiba
Hokkaido University Hospital, Sapporo, Hokkaido
National Hospital Organization Himeji Medical Center, Himeji, Hyogo
Kobe University Hospital, Kobe, Hyogo
Kitasato University Hospital, Sagamihara, Kanagawa
Sendai Kousei Hospital, Sendai, Miyagi
Kansai Medical University Hospital, Hirakata, Osaka
Kindai University Hospital, Osakasayama, Osaka
Saitama Cancer Center, Kitaadachi-gun, Saitama
Nippon Medical School - Nippon Medical School Hospital - Cancer Center, Bunkyo-ku, Tokyo
Tottori University Hospital, Yonago, Tottori
National Hospital Organization-Yamaguchi-Ube Medical Center (Sanyo Hospital), Ube, Yamaguchi
National Hospital Organization Kyushu Medical Center, Fukuoka, Not set
Niigata Cancer Center Hospital, Niigata, Not set
Osaka International Cancer Institute, Osaka, Not set
Chungbuk National University Hospital, Cheongju-si, Chungcheongbugdo
Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do
Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnamdo
Severance Hospital, Yonsei University Health System - Oncology Department, Seoul, Seoul Teugbyeolsi
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi
Chonnam National University Hwasun Hospital, Hwasun Gun, Not set
Samsung Medical Center - Oncology Department, Seoul, Not set
Beacon Hospital, Petaling Jaya, Selangor
Columbia Asia Hospital Bukit Rimau, Shah Alam, Selangor
Sunway Medical Centre, Subang Jaya, Selangor
University Hospital Kebangsaan Malaysia, Cheras, Not set
Gleneagles Penang Medical Center, George Town,, Not set
University Malaya Medical Centre, Kuala Lumpur, Not set
Sunway Medical Centre Penang, Perai, Not set
Instituto Nacional de Cancerología, Mexico, Distrito Federal
Oncare Viaducto Nápoles, Cdmx, Not set
Oncología Integral Satélite, Naucalpan, Not set
Hospital Universitrio Dr. José Eleuterio González. Servicio de Oncologia, Nuevo León, Not set
Clinica Integral Internacional de Oncologia S. de R.L. de C.V., Puebla, Not set
ONCARE Treatment Center, San Pedro Garza García, Not set
Nederlands Kanker Instituut, Amsterdam, Not set
Radboud University Medical Center | Afdeling Interne Geneeskunde, Nijmegen, Not set
Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy - Nowotworow Pluca i Klatki Piersiowej, Warsaw, Mazowieckie
Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy - Nowotworow Pluca i Klatki Piersiowej, Warsaw, Mazowieckie
Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Not set
Swietokrzyskie Centrum Onkologii, Kielce, Not set
Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Lodzi, Lodz, Not set
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwock, Not set
Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan, Not set
Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii, Wroclaw, Not set
Hospital Pedro Hispano | Clinical Research Center, Matosinhos, Porto
Unidade Local Saúde Coimbra, E.P.E, Coimbra, Not set
Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica, Lisboa, Not set
CHULN - Hospital Pulido Valente, Lisboa, Not set
IPO Porto, Porto, Not set
Radiotherapy Center Cluj SRL, Flore?ti, Comuna Floresti
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu (IOB); Oncologie Medicala II, Bucuresti, Not set
Spitalul Clinic Coltea, Bucuresti, Not set
CardioMed S.R.L., Cluj-Napoca, Not set
Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Not set
Sc Oncolab Srl, Craiova, Not set
Centrul de Oncologie Sfantul Nectarie, Craiova, Not set
S.C Ovidius Clinical Hospital SRL - Oncology Department, Ovidiu, Not set
Oncocenter, Timisoara, Not set
Raffles Cancer Centre, Singapore, Not set
OncoCare Cancer Centre | Gleneagles Medical Centre, Singapore, Not set
Tan Tock Seng Hospital, Singapore, Not set
Curie Oncology | Farrer, Singapore, Not set
POKO Poprad s.r.o., Poprad, Not set
Fakultna nemocnica Trnava, Trnava, Not set
Hospital Universitario Puerta De Hierro De Majadahonda - Oncologia, Majadahonda, Madrid
Complejo Hospitalario Universitario A Coruna (CHUAC), A Coruna, Not set
Institut Catala d'Oncologia (ICO) - Hospital Universitari Germans Trias i Pujol (HUGTP) Location, Badalona, Not set
Hospital Quiron Dexeus - Oncologia, Barcelona, Not set
Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona, Not set
Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Not set
Hospital General Universitario Gregorio Maranon | Oncologia, Madrid, Not set
Hospital Universitario Ramon Y Cajal - Oncologia, Madrid, Not set
Hospital Universitario Fundacion Jimenez Diaz- Oncology Service, Madrid, Not set
Hospital Universitario De Navarra - Oncologia, Pamplona, Not set
Fundacion Instituto Valenciano de Oncologia (IVO, Valencia, Not set
Hospital Universitario Y Politecnico La Fe - Oncologia, Valencia, Not set
Skåne University Hospital, Lund, Not set
Norrland University Hospital - Cancercentrum, Umeå, Not set
Kantonsspital Baden, Baden, Aargau
HFR Freiburg - Kantonsspital, Fribourg, Not set
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Kaohsiung
National Cheng Kung University Hospital, Tainan, TNN
Chung Shan Medical University Hospital, Taichung, Not set
Taichung Veterans General Hospital, Taichung, Not set
Chi-Mei Medical Center, Liouyine, Tainan, Not set
National Taiwan University Hospital (NTUH) - Cancer Research Center, Taipei, Not set
National Taiwan University Hospital, Taipei, Not set
Taipei Veterans General Hospital, Taipei, Not set
Ankara Bilkent Sehir Hastanesi, Bilkent Ankara, Not set
Marmara University Hospital, Istanbul, Not set
Ege Universitesi Tip Fakultesi, Izmir, Not set
Istanbul Medeniyet Üniversitesi Göztepe Süleyman Yalçin Sehir Hastanesi, Kadikoy, Not set
I.A.Ü. VM Medical Park Florya Hastanesi, Kucukcekmece, Not set
Sakarya Universitesi Egitim ve Arastirma Hastanesi, Sakarya, Not set
Ankara Etlik Sehir Hastanesi, Yenimahalle, Not set
Adana Sehir Egitim ve Arastirma Hastanesi, Yuregir, Not set
LLC "RDP Ukraine" - Medical Department, Dnipro, Not set
Private Enterprise Private Production Company "Acinus", Treatment and Diagnostic Center, Kropyvnytskyi, Not set
Kyiv City Clinical Oncology Center - Department of Chemotherapy #1, Kyiv, Not set
Limited Liability Company "MedOffice Group Medical Center", Kyiv, Not set
Medical Center LLC "Verum Expert Clinic", Kyiv, Not set
Volyn Regional Oncology Center, Lutsk, Not set
Municipal Enterprise 'Rivne Regional Antitumor Center" of the Rivne Regional Council", Rivne, Not set
MNCE "Uzhhorod City Multidisciplinary Clinical Hospital" -Oncology Department, Uzhhorod, Not set
Torbay Hospital, Torquay, Devon
Belfast City Hospital, Belfast, North Ireland
Royal Surrey County Hospital, Guildford, Surrey
Velindre University NHS Trust | Velindre Cancer Centre - Clinical Trials Unit, Cardiff, Not set
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations
Local Institution - 0303, Hot Springs, Arkansas
Local Institution - 0307, Cerritos, California
Local Institution - 0308, Cerritos, California
Local Institution - 0309, Cerritos, California
Local Institution - 0311, Long Beach, California
Local Institution - 0290, Los Angeles, California
Local Institution - 0283, Los Angeles, California
Local Institution - 0328, Whittier, California
Local Institution - 0289, Aurora, Colorado
Local Institution - 0304, Newark, Delaware
Local Institution - 0282, Miami, Florida
Local Institution - 0296, Pembroke Pines, Florida
Local Institution - 0294, Atlanta, Georgia
Local Institution - 0278, Chicago, Illinois
Local Institution - 0280, Chicago, Illinois
Decatur Memorial Hospital, Decatur, Illinois
Local Institution - 0324, O'Fallon, Illinois
Local Institution - 0286, Covington, Louisiana
Local Institution - 0288, Boston, Massachusetts
Local Institution - 0287, Boston, Massachusetts
Local Institution - 0313, Minneapolis, Minnesota
Local Institution - 0284, Kansas City, Missouri
Local Institution - 0312, New York, New York
Local Institution - 0279, New York, New York
Clinical Research Alliance, Westbury, New York
Local Institution - 0285, White Plains, New York
Local Institution - 0276, Durham, North Carolina
Local Institution - 0316, Eugene, Oregon
Local Institution - 0310, Philadelphia, Pennsylvania
Local Institution - 0281, Greenville, South Carolina
Local Institution - 0315, Austin, Texas
Local Institution - 0314, Houston, Texas
Local Institution - 0305, Tyler, Texas
Local Institution - 0277, Midlothian, Virginia
Local Institution - 0301, Roanoke, Virginia
Local Institution - 0302, Winchester, Virginia
Local Institution - 0345, Buenas Aires, Buenos Aires
Local Institution - 0011, Ciudad autónoma de Buenos Aires, Buenos Aires
Local Institution - 0214, ABB, Ciudad Autónoma De Buenos Aires
Local Institution - 0143, Cordoba, Córdoba
Local Institution - 0137, Río Cuarto, Córdoba
Local Institution - 0142, Rosario, Santa Fe
Local Institution - 0317, Buenos Aires, Not set
Local Institution - 0346, Buenos Aires, Not set
Local Institution - 0012, Ciudad Autónoma de Buenos Aires, Not set
Local Institution - 0035, Brisbane, Queensland
Local Institution - 0197, Ballarat Central, Victoria
Local Institution - 0031, Heidelberg, Victoria
Local Institution - 0274, Melbourne, Victoria
Local Institution - 0028, Subiaco, Western Australia
Local Institution - 0292, Graz, Steiermark
Local Institution - 0268, Innsbruck, Tirol
Local Institution - 0267, Salzburg, Not set
Local Institution - 0270, St. Polten, Not set
Local Institution - 0269, Wien, Not set
Local Institution - 0187, Manaus, Amazonas
Local Institution - 0147, Fortaleza, Ceará
Local Institution - 0157, Vitória, Espírito Santo
Local Institution - 0199, Porto Alegre, Rio Grande Do Sul
Local Institution - 0164, São José do Rio Preto, São Paulo
Local Institution - 0153, Rio de Janeiro, Not set
Local Institution - 0144, São Paulo, Not set
Local Institution - 0149, São Paulo, Not set
Local Institution - 0218, Kelowna, British Columbia
Local Institution - 0217, Victoria, British Columbia
Local Institution - 0265, Ottawa, Ontario
Local Institution - 0215, Montréal, Quebec
Local Institution - 0219, Montréal, Quebec
Local Institution - 0350, Saint-Jerome, Quebec
Local Institution - 0216, Sherbrooke, Quebec
Local Institution - 0138, Santiago, Región Metropolitana De Santiago
Local Institution - 0021, Santiago, Región Metropolitana De Santiago
Local Institution - 0017, Santiago, Región Metropolitana De Santiago
Local Institution - 0018, Santiago, Región Metropolitana De Santiago
Local Institution - 0016, Viña del Mar, Valparaíso
Local Institution - 0195, Medellín, Antioquia
Local Institution - 0201, Rionegro, Antioquia
Local Institution - 0194, Barranquilla, Atlántico
Local Institution - 0182, Puerto Colombia, Atlántico
Local Institution - 0181, Montería, COR
Local Institution - 0327, Bogota, Cundinamarca
Local Institution - 0183, Cali, Valle Del Cauca
Local Institution - 0349, Medellin, Not set
Local Institution - 0089, Bordeaux, Aquitaine
Local Institution - 0272, Dijon, Côte-d'Or
Local Institution - 0098, Toulouse, Haute-Garonne
Local Institution - 0095, Montpellier, Hérault
Local Institution - 0099, Rennes, Ille-et-Vilaine
Local Institution - 0092, Saint Herblain, Loire-Atlantique
Local Institution - 0091, Reims, Marne
Local Institution - 0097, Villejuif, Paris
Local Institution - 0093, Marseille, Provence-Alpes-Côte-d'Azur
Local Institution - 0096, Clermont-Ferrand, Puy-de-Dôme
Local Institution - 0090, Lyon, Rhône-Alpes
Local Institution - 0094, Lille, Not set
Local Institution - 0088, Paris, Not set
Local Institution - 0320, Esslingen, Baden-Württemberg
Local Institution - 0256, Augsburg, Bayern
Local Institution - 0271, München, Bayern
Local Institution - 0306, Frankfurt, Hessen
Local Institution - 0333, Langen, Hessen
Local Institution - 0257, Hannover, Niedersachsen
Local Institution - 0293, Düsseldorf, Nordrhein-Westfalen
Local Institution - 0263, Essen, Nordrhein-Westfalen
Local Institution - 0254, Leipzig, Sachsen
Local Institution - 0255, Lübeck, Schleswig-Holstein
Local Institution - 0261, Berlin, Not set
Local Institution - 0260, Berlin, Not set
Local Institution - 0259, Bonn, Not set
Local Institution - 0258, Dresden, Not set
Local Institution - 0262, Heidelberg, Not set
Local Institution - 0291, Ulm, Not set
Local Institution - 0042, Athens, Attikí
Local Institution - 0038, Athens, Attikí
Local Institution - 0086, Heraklion, Irakleío
Local Institution - 0043, Athens, Not set
Local Institution - 0266, New Delhi, Delhi
Local Institution - 0206, New Delhi, Delhi
Local Institution - 0131, Mumbai, Maharashtra
Local Institution - 0134, Nagpur, Maharashtra
Local Institution - 0125, Chennai, Tamil Nadu
Local Institution - 0130, Hyderabad, Telangana
Local Institution - 0133, Varanasi, Uttar Pradesh
Local Institution - 0352, New Delhi, Not set
Local Institution - 0186, Petah Tikva, HaMerkaz
Local Institution - 0044, Ramat Gan, HaMerkaz
Local Institution - 0048, Hadera, HaTsafon
Local Institution - 0123, Haifa, HaTsafon
Local Institution - 0047, Jerusalem, Yerushalayim
Local Institution - 0051, Napoli, Campania
Local Institution - 0049, Bologna, Emilia-Romagna
Local Institution - 0057, Aviano, Friuli-Venezia Giulia
Local Institution - 0054, Genova, Liguria
Local Institution - 0053, Pontedera, Pisa
Local Institution - 0055, Prato, Toscana
Local Institution - 0052, Milano, Not set
Local Institution - 0058, Napoli, Not set
Local Institution - 0061, Novara, Not set
Local Institution - 0056, Padova, Not set
Local Institution - 0062, Roma, Not set
Local Institution - 0236, Nagoya, Aichi
Local Institution - 0230, Chiba-shi, Chiba
Local Institution - 0240, Matsuyama, Ehime
Local Institution - 0226, Otashi, Gunma
Local Institution - 0222, Sapporo, Hokkaido
Local Institution - 0232, Kanazawa, Ishikawa
Local Institution - 0234, Isehara, Kanagawa
Local Institution - 0237, Yokohama, Kanagawa
Local Institution - 0246, Tsu, Mie
Local Institution - 0223, Sendai-shi, Miyagi
Local Institution - 0238, Suita, Osaka
Local Institution - 0227, Hidaka, Saitama
Local Institution - 0224, Ina-machi, Saitama
Local Institution - 0231, Bunkyo-ku, Tokyo
Local Institution - 0229, Chuo-ku, Tokyo
Local Institution - 0228, Koto, Tokyo
Local Institution - 0245, Shinagawa, Tokyo
Local Institution - 0233, Shinjuku-ku, Tokyo
Local Institution - 0242, Fukuoka, Not set
Local Institution - 0225, Fukushima, Not set
Local Institution - 0243, Hiroshima, Not set
Local Institution - 0244, Kagoshima, Not set
Local Institution - 0235, Kyoto, Not set
Local Institution - 0241, Okayama, Not set
Local Institution - 0239, Osaka, Not set
Local Institution - 0066, Goyang-si, Kyǒnggi-do
Local Institution - 0067, Seongnam, Kyǒnggi-do
Local Institution - 0068, Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0063, Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0071, Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0064, Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0065, Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0069, Daegu, Taegu-Kwangyǒkshi
Local Institution - 0264, Tijuana, Baja California
Local Institution - 0177, Mexico City, DIF
Local Institution - 0329, Mexico City, Distrito Federal
Local Institution - 0178, Guadalajara, Jalisco
Local Institution - 0175, Monterrey, Nuevo León
Local Institution - 0176, Monterrey, Nuevo León
Local Institution - 0173, Oaxaca de Juarez, Oaxaca
Local Institution - 0179, Merida, Yucatán
Local Institution - 0174, Chihuahua, Not set
Local Institution - 0074, Biala Podlaska, Lubelskie
Local Institution - 0072, Warszawa, Mazowieckie
Local Institution - 0220, Warszawa, Mazowieckie
Local Institution - 0076, Opole, Opolskie
Local Institution - 0189, Skórzewo, Wielkopolskie
Local Institution - 0221, Łódź, Łódzkie
Local Institution - 0198, Lisbon, Lisboa
Local Institution - 0106, Lisbon, Lisboa
Local Institution - 0109, Lisbon, Lisboa
Local Institution - 0124, Coimbra, Not set
Local Institution - 0141, Lisboa, Not set
Local Institution - 0111, Porto, Not set
Local Institution - 0253, Porto, Not set
Local Institution - 0212, Bistrita, Bistrița-Năsăud
Local Institution - 0213, Bucharest, București
Local Institution - 0079, Florești, Cluj
Local Institution - 0078, Craiova, Dolj
Local Institution - 0084, Ploiești, Prahova
Local Institution - 0211, Dumbravita, Timiș
Local Institution - 0085, Timișoara, Timiș
Local Institution - 0083, București, Not set
Local Institution - 0077, Cluj, Not set
Local Institution - 0081, Iași, Not set
Local Institution - 0080, Iași, Not set
Local Institution - 0351, East London, Eastern Cape
Local Institution - 0342, Parktown, Gauteng
Local Institution - 0336, Pretoria, Gauteng
Local Institution - 0341, Pretoria, Gauteng
Local Institution - 0340, Soweto, Gauteng
Local Institution - 0105, A Coruña, A Coruña [La Coruña]
Local Institution - 0100, Elche, Alicante
Local Institution - 0102, Barcelona, Barcelona [Barcelona]
Local Institution - 0172, Hospitalet, Barcelona [Barcelona]
Local Institution - 0140, Barcelona, Catalunya [Cataluña]
Local Institution - 0139, San Sebastian, Gipuzkoa
Local Institution - 0104, Madrid, Madrid, Comunidad De
Local Institution - 0108, Madrid, Madrid, Comunidad De
Local Institution - 0101, Malaga, Málaga
Local Institution - 0210, Valencia, Valenciana, Comunitat
Local Institution - 0107, Madrid, Not set
Local Institution - 0103, Sevilla, Not set
Local Institution - 0252, Malmö, Skåne Län [se-12]
Local Institution - 0026, Stockholm, Stockholms Län [se-01]
Local Institution - 0025, Uppsala, Uppsala Län [se-03]
Local Institution - 0024, Örebro, Örebro Län [se-18]
Local Institution - 0247, Linköping, Östergötlands Län [se-05]
Local Institution - 0250, st.Gallen, Sankt Gallen
Local Institution - 0249, Lausanne, Vaud
Local Institution - 0251, Zürich, Not set
Local Institution - 0323, Abu Dhabi, Abū Z̧aby
Local Institution - 0318, Abu Dhabi, Abū Z̧aby
Local Institution - 0322, Al Ain, Abū Z̧aby
Local Institution - 0319, Abu Dhabi, Not set
Local Institution - 0208, Truro, England
Local Institution - 0204, London, London, City Of
Local Institution - 0209, London, London, City Of
Local Institution - 0171, Belfast, Not set
Local Institution - 0004, London, Not set
Local Institution - 0001, Manchester, Not set
Local Institution - 0006, Nottingham, Not set
Conditions: Breast Neoplasms
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Active Not Recruiting
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response... Read More
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Florida Cancer Specialists, West Palm Beach, Florida +92 locations
Florida Cancer Specialists, West Palm Beach, Florida
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia
Illinois Cancer Care, Peoria, Illinois
New England Cancer Specialists, Scarborough, Maine
Dana Farber Cancer Institute, Boston, Massachusetts
Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan
Mercy Research - St. Louis, Saint Louis, Missouri
Clinical Research Alliance, Westbury, New York
Fox Chase Cancer Center, Philadelphia, Pennsylvania
Rhode Island Hospital, Providence, Rhode Island
Hollings Cancer Center, Charleston, South Carolina
Greco-Hainesworth Centers for Research, Chattanooga, Tennessee
West Clinic, Germantown, Tennessee
Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee
Institut Jules Bordet, Anderlecht, Not set
Jessa Zkh (Campus Virga Jesse), Hasselt, Not set
UZ Leuven Gasthuisberg, Leuven, Not set
AZ St Maarten Campus Leopoldstr, Mechelen, Not set
CHU UCL Mont-Godinne, Mont-godinne, Not set
Vitaz, Sint Niklaas, Not set
Zentralklinik Bad Berka GmbH, Bad Berka, Not set
Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, Not set
Helios Klinikum Emil von Behring GmbH, Berlin, Not set
Klinikum Chemnitz gGmbH, Chemnitz, Not set
KEM/Evang. Kliniken Essen Mitte gGmbH, Essen, Not set
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH, Georgsmarienhütte, Not set
LungenClinic Großhansdorf GmbH, Großhansdorf, Not set
Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, Not set
Universitätsklinikum Schleswig-Holstein, Lübeck, Not set
Asklepios Klinik Gauting, München-Gauting, Not set
Sotiria Thoracic Diseases Hospital of Athens, Athens, Not set
Errikos Dynan Hospital, Athens, Not set
University Hospital of Larissa, Larissa, Not set
Euromedical General Clinic of Thessaloniki, Thessaloniki, Not set
Diavalkaniko Hospital, Thessaloniki, Not set
Orszagos Koranyi Pulmonologiai Intezet, Budapest, Not set
Pécsi Tudományegyetem, Pécs, Not set
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int., Szolnok, Not set
Tudogyogyintezet Torokbalint, Torokbalint, Not set
AUSL della Romagna, Ravenna, Emilia-Romagna
ASL 3 Genovese, Genova, Liguria
Irccs Istituto Europeo di Oncologia (IEO), Milano, Lombardia
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia
Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Marche
Chungbuk National University Hospital, Cheongju-si, Not set
Chilgok Kyungpook National University Medical Center, Daegu, Not set
Samsung Changwon Hospital, Gyeongsangnam-do, Not set
Gyeongsang National University Hospital, Gyeongsangnam-do, Not set
Seoul National University Bundang Hospital, Seongnam-si, Not set
Asan Medical Center, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Ulsan University Hosiptal, Ulsan, Not set
Health Pharma Professional Research, Cdmx, Mexico CITY (federal District)
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Morelia, Not set
Uniwersyteckie Centrum Kliniczne, Gda?sk, Not set
Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II, Kraków, Not set
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie, Olsztyn, Not set
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Not set
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Not set
Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie, Warszawa, Not set
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, LA Coruna
Hospital del Mar, Barcelona, Not set
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set
Hospital de la Santa Creu i Sant Pau, Barcelona, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Clinico Universitario Virgen de la Victoria, Malaga, Not set
Hospital Universitario Virgen del Rocio, Sevilla, Not set
E-DA Hospital, Kaohsiung, Not set
Taichung Veterans General Hospital, Taichung, Not set
National Cheng Kung University Hospital, Tainan, Not set
Taipei Veterans General Hospital, Taipei, Not set
Adana Baskent University Hospital, Adana, Not set
Memorial Ankara Hastanesi, Ankara, Not set
Liv Hospital Ankara, Ankara, Not set
Ankara City Hospital, Ankara, Not set
Uludag Uni Hospital, Bursa, Not set
Pamukkale University School Of Medicine, Denizli, Not set
Dicle University Faculty of Medicine, Diyarbakir, Not set
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Not set
Ba?c?lar Medipol Mega Üniversite Hastanesi, Istanbul, Not set
Istanbul Uni Cerrahpasa Medical Faculty Hospital, Istanbul, Not set
Ac?badem Altunizade Hastanesi, Istanbul, Not set
Izmir Medical Point Hospital, Izmir, Not set
Kocaeli University Faculty of Medicine, Izmit, Not set
Goztepe Prof.Dr. Suleyman Yalcin City Hospital, Kadiköy, Not set
Medikal Park Samsun, Samsun, Not set
TC Necmettin Erbakan University Meram Medical Faculty Hospital, Selçuklu, Not set
Blackpool Victoria Hospital, Blackpool, Not set
Christie NHS Foundation Trust, GB Manchester, Not set
Castle Hill Hospital, Hull, Not set
St James University Hospital, Leeds, Not set
Leicester Royal Infirmary, Leicester, Not set
Guy's Hospital, London, Not set
Conditions: Small-Cell Lung Cancer
37 - 48 of 302